Literature DB >> 8336729

Oncogenic activation of c-ABL by mutation within its last exon.

A Goga1, J McLaughlin, A M Pendergast, K Parmar, A Muller, N Rosenberg, O N Witte.   

Abstract

The c-ABL proto-oncogene is a predominantly nuclear localized tyrosine kinase. A random mutagenesis scheme was used to isolate c-ABL mutants whose expression produced a transformed phenotype in rodent fibroblast cells. An in-frame deletion within the central region of the last exon was identified in one ABL mutant. The mechanism of c-ABL oncogenic activation by mutation within the last exon differs both functionally and structurally from those of v-ABL and BCR/ABL. This class of ABL mutants shows increased tyrosine phosphorylation of cellular proteins in vivo but low levels of autophosphorylation. Last-exon ABL mutants are distinguished from v-ABL or BCR/ABL by their inability to transform primary bone marrow cells or support the growth of transformed pre-B cells. These findings define a new mechanism of oncogenic activation for the ABL kinase through mutations in the last exon which do not require amino-terminal deletions or mutations within the src homology regions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8336729      PMCID: PMC360140          DOI: 10.1128/mcb.13.8.4967-4975.1993

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  33 in total

Review 1.  SH2 and SH3 domains: from structure to function.

Authors:  T Pawson; G D Gish
Journal:  Cell       Date:  1992-10-30       Impact factor: 41.582

2.  Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.

Authors:  J R McWhirter; J Y Wang
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

3.  c-abl has a sequence-specific enhancer binding activity.

Authors:  R Dikstein; D Heffetz; Y Ben-Neriah; Y Shaul
Journal:  Cell       Date:  1992-05-29       Impact factor: 41.582

4.  BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.

Authors:  A J Muller; J C Young; A M Pendergast; M Pondel; N R Landau; D R Littman; O N Witte
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

5.  Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA.

Authors:  E T Kipreos; J Y Wang
Journal:  Science       Date:  1992-04-17       Impact factor: 47.728

6.  Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor.

Authors:  A M Pendergast; A J Muller; M H Havlik; R Clark; F McCormick; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

7.  En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase.

Authors:  A J Muller; A M Pendergast; K Parmar; M H Havlik; N Rosenberg; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

8.  Identification of a protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho.

Authors:  P Cicchetti; B J Mayer; G Thiel; D Baltimore
Journal:  Science       Date:  1992-08-07       Impact factor: 47.728

9.  Lymphoid cells transformed by Abelson virus require the v-abl protein-tyrosine kinase only during early G1.

Authors:  Y Y Chen; N Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

10.  SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence.

Authors:  A M Pendergast; M L Gishizky; M H Havlik; O N Witte
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

View more
  7 in total

1.  The amphiphysin-like protein 1 (ALP1) interacts functionally with the cABL tyrosine kinase and may play a role in cytoskeletal regulation.

Authors:  L Kadlec; A M Pendergast
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

2.  Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia.

Authors:  T R Golub; A Goga; G F Barker; D E Afar; J McLaughlin; S K Bohlander; J D Rowley; O N Witte; D G Gilliland
Journal:  Mol Cell Biol       Date:  1996-08       Impact factor: 4.272

Review 3.  Molecular biology of chronic myeloid leukemia.

Authors:  Y Maru
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

4.  A crucial role in cell spreading for the interaction of Abl PxxP motifs with Crk and Nck adaptors.

Authors:  Susumu Antoku; Kalle Saksela; Gonzalo M Rivera; Bruce J Mayer
Journal:  J Cell Sci       Date:  2008-09-15       Impact factor: 5.285

5.  Ras complements the carboxyl terminus of v-Abl protein in lymphoid transformation.

Authors:  K Parmar; N Rosenberg
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

6.  The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products.

Authors:  S T Wen; P K Jackson; R A Van Etten
Journal:  EMBO J       Date:  1996-04-01       Impact factor: 11.598

7.  Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.

Authors:  L Puil; J Liu; G Gish; G Mbamalu; D Bowtell; P G Pelicci; R Arlinghaus; T Pawson
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.